SCHEMBL2189880

SCHEMBL2189880

NC(=O)CNC(=O)C(N)CC(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ECE1 P42892 1/20 0.34
DPP7 Q9UHL4 2/20 0.33
METAP1 P53582 1/20 0.33
ALOX15 P16050 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
KMT2A Q03164 1/20 0.32
AURKA O14965 1/20 0.32
PRKCB P05771 1/20 0.32
SRC P12931 1/20 0.32
TNFRSF1A P19438 1/20 0.32
STK3 Q13188 1/20 0.32
RRM1 P23921 1/20 0.31
DPP4 P27487 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274426 1.00 CA12 (0.35) CA12CA1CA2ECE1DPP7
SCHEMBL757140 0.92 CA12 (0.33) CA12CA1CA2ECE1DPP7
SCHEMBL3451522 0.87 ALDH1A1 (0.45) CA12CA1CA2ECE1ALOX15
SCHEMBL16685 0.87 ALDH1A1 (0.45) CA12CA1CA2ECE1ALOX15
SCHEMBL24709575 0.87 SLC22A6 (0.37) ECE1ALOX15BLMPMP22KMT2A
Hydroxyamine SCHEMBL8490496 0.85 ALDH1A1 (0.44) CA12CA1CA2ECE1ALOX15
Glycine SCHEMBL1694000 0.82 ALDH1A1 (0.41) CA12CA1CA2ECE1BLM
SCHEMBL2633077 0.82 DPP7 (0.36) DPP7METAP1ALOX15BLMPMP22
SCHEMBL2739489 0.82 DPP7 (0.36) DPP7METAP1ALOX15BLMPMP22
SCHEMBL5509836 0.81 SLC7A5 (0.48) DPP4DPP8DPP9ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP CA12 282/4885CA1 905/4885CA2 3392/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP CA12 282/4885CA1 905/4885CA2 3392/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS CA12 135/4885CA1 386/4885CA2 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.